BioSpace News Archive

Biotech Bay

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 18, 2023

Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 810 shares of common stock of the company and 31,690 restricted stock units of the company’s common stock to 23 newly hired non-executive officers of the company.

May 18, 2023
·
2 min read
Business

Dr. Linda Tolbert selected as executive medical director for the Washington Permanente Medical Group

A new era has launched for the Washington Permanente Medical Group, with the selection of its new executive medical director, Linda Tolbert, MD, JD, EdD, MPH, who officially began her position on May 15, 2023.

May 18, 2023
·
3 min read
BioMidwest

AMA Celebrates Graduates with Tribute to Medical School Class of 2023

The American Medical Association announced a virtual celebration to honor the newest group of medical school graduates.

May 18, 2023
·
1 min read
Business

Kane Biotech to Release First Quarter 2023 Financial Results on May 25, 2023 – Conference Call to Follow

Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its first quarter 2023 financial results after market close on Thursday, May 25, 2023.

May 18, 2023
·
3 min read
Business

Ambrx Appoints Stephen Glover as Chairman of its Board of Directors

Ambrx Biopharma Inc., or Ambrx, announced that Stephen Glover has joined the Company’s Board of Directors as Chairman.

May 18, 2023
·
5 min read
Biotech Bay

Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company today announced that its 505(b)(2) new drug application (NDA) for STS101, a novel and investigational therapeutic product candidate for the acute treatment of migraine, has been accepted for review by the FDA.

May 18, 2023
·
7 min read
Business

Perimeter Medical Imaging AI Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update

Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) – a commercial-stage medical technology company – announced it will report its first quarter 2023 financial and operating results after the close of U.S. financial markets on Thursday, May 25, 2023.

May 18, 2023
·
4 min read